JP2024009962A5 - - Google Patents
Info
- Publication number
- JP2024009962A5 JP2024009962A5 JP2023177262A JP2023177262A JP2024009962A5 JP 2024009962 A5 JP2024009962 A5 JP 2024009962A5 JP 2023177262 A JP2023177262 A JP 2023177262A JP 2023177262 A JP2023177262 A JP 2023177262A JP 2024009962 A5 JP2024009962 A5 JP 2024009962A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- sequence shown
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622292P | 2018-01-26 | 2018-01-26 | |
| US62/622,292 | 2018-01-26 | ||
| PCT/US2019/014978 WO2019147831A1 (en) | 2018-01-26 | 2019-01-24 | Anti-tmprss2 antibodies and antigen-binding fragments |
| JP2020540397A JP7834965B2 (ja) | 2018-01-26 | 2019-01-24 | 抗ｔｍｐｒｓｓ２抗体および抗原結合断片 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540397A Division JP7834965B2 (ja) | 2018-01-26 | 2019-01-24 | 抗ｔｍｐｒｓｓ２抗体および抗原結合断片 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024009962A JP2024009962A (ja) | 2024-01-23 |
| JP2024009962A5 true JP2024009962A5 (enExample) | 2026-05-08 |
Family
ID=66102175
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540397A Active JP7834965B2 (ja) | 2018-01-26 | 2019-01-24 | 抗ｔｍｐｒｓｓ２抗体および抗原結合断片 |
| JP2023177262A Pending JP2024009962A (ja) | 2018-01-26 | 2023-10-13 | 抗ｔｍｐｒｓｓ２抗体および抗原結合断片 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540397A Active JP7834965B2 (ja) | 2018-01-26 | 2019-01-24 | 抗ｔｍｐｒｓｓ２抗体および抗原結合断片 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10941213B2 (enExample) |
| EP (1) | EP3638698B1 (enExample) |
| JP (2) | JP7834965B2 (enExample) |
| KR (2) | KR102911478B1 (enExample) |
| CN (2) | CN111936517B (enExample) |
| AU (2) | AU2019211406C1 (enExample) |
| BR (1) | BR112020015112A2 (enExample) |
| CA (1) | CA3089377A1 (enExample) |
| CY (1) | CY1124182T1 (enExample) |
| DK (1) | DK3638698T3 (enExample) |
| ES (1) | ES2864529T3 (enExample) |
| HR (1) | HRP20210876T1 (enExample) |
| HU (1) | HUE054403T2 (enExample) |
| IL (2) | IL276164B2 (enExample) |
| LT (1) | LT3638698T (enExample) |
| MA (1) | MA46731B1 (enExample) |
| MD (1) | MD3638698T2 (enExample) |
| MX (2) | MX2020007888A (enExample) |
| PL (1) | PL3638698T3 (enExample) |
| PT (1) | PT3638698T (enExample) |
| RS (1) | RS61825B1 (enExample) |
| SG (1) | SG11202006898TA (enExample) |
| SI (1) | SI3638698T1 (enExample) |
| SM (1) | SMT202100307T1 (enExample) |
| WO (1) | WO2019147831A1 (enExample) |
| ZA (1) | ZA202004494B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI702229B (zh) * | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| BR112020015112A2 (pt) | 2018-01-26 | 2021-04-06 | Regeneron Pharmaceuticals, Inc. | Anticorpos anti-tmprss2 e fragmentos que ligam antígenos |
| EP4034564A4 (en) | 2019-09-23 | 2023-12-13 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES |
| US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| BR112022014278A2 (pt) | 2020-01-24 | 2022-09-20 | Regeneron Pharma | Conjugados de composto proteico-antiviral |
| EP4103619A1 (en) * | 2020-02-10 | 2022-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss2 antibodies and antigen-binding fragments |
| WO2021190980A1 (en) | 2020-03-22 | 2021-09-30 | Quadrucept Bio Limited | Multimers for viral strain evolution |
| CR20220552A (es) | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| KR20230002612A (ko) * | 2020-04-13 | 2023-01-05 | 매든 어드바이저스 엘엘씨 | Ace2-표적화 조성물 및 covid-19의 치료 방법 |
| IL297237B2 (en) | 2020-04-17 | 2025-08-01 | Regeneron Pharma | Detection assays for coronavirus neutralizing antibodies |
| US20230149536A1 (en) | 2020-04-17 | 2023-05-18 | Vyriad, Inc. | Compositions for treating and/or preventing coronavirus infections |
| AU2021282179A1 (en) | 2020-05-26 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments |
| MX2022014852A (es) | 2020-06-03 | 2023-02-01 | Regeneron Pharma | Métodos para tratar o prevenir infecciones por sars-cov-2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2. |
| US12097212B2 (en) * | 2020-06-08 | 2024-09-24 | Brigham Young University | Use of cationic steroidal antimicrobial compounds to deactivate coronavirus |
| WO2021255217A1 (en) | 2020-06-19 | 2021-12-23 | Heidelberg Pharma Research Gmbh | Amatoxin and amatoxin conjugates for use in inhibition of rna virus replication |
| CN111986818A (zh) * | 2020-08-21 | 2020-11-24 | 南通大学 | 一种基于tmprss2的新冠covid-19治疗药物筛选系统 |
| IL300917A (en) | 2020-09-04 | 2023-04-01 | Univ Rutgers | Sars-cov-2 vaccines and antibodies |
| CN112795583A (zh) * | 2020-11-16 | 2021-05-14 | 上海大学 | 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法 |
| WO2022115503A1 (en) | 2020-11-25 | 2022-06-02 | Dupont Nutrition Biosciences Aps | Treatment and prevention of coronavirus infection |
| CN112538494A (zh) * | 2020-12-08 | 2021-03-23 | 武汉华美生物工程有限公司 | 一种tmprss2突变体蛋白及其表达载体、表达工程菌和制备方法 |
| WO2022133182A1 (en) * | 2020-12-18 | 2022-06-23 | Chan Zuckerberg Biohub, Inc. | Method of treating coronavirus infection |
| WO2022184659A1 (en) | 2021-03-01 | 2022-09-09 | Quadrucept Bio Limited | Antibody domains & multimers |
| WO2022187626A1 (en) | 2021-03-05 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| EP4370210A1 (en) | 2021-07-14 | 2024-05-22 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| US20250277059A1 (en) * | 2022-04-12 | 2025-09-04 | Riken | Antibody used to treat coronavirus infection |
| WO2023220712A1 (en) * | 2022-05-13 | 2023-11-16 | The Trustees Of Columbia University In The City Of New York | Host proteases essential for parainfluenza spread in the human lung: potential targets for antiviral interventions |
| CN116003611B (zh) * | 2022-08-17 | 2024-02-27 | 中南大学湘雅医院 | 抗tmprss2抗体及其用途 |
| WO2024252183A1 (en) * | 2023-06-08 | 2024-12-12 | Institut Pasteur | Single domain antibodies directed against human transmembrane- serine protease 2 (tmprss2) |
| WO2025072792A1 (en) * | 2023-09-28 | 2025-04-03 | The Regents Of The University Of California | Methods for identifying and treating diseases characterized by allele specific expression |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US5693489A (en) | 1984-03-30 | 1997-12-02 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| ATE429643T1 (de) | 2000-07-12 | 2009-05-15 | Agensys Inc | Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2008127347A1 (en) | 2006-07-21 | 2008-10-23 | Diadexus, Inc. | Pro115 antibody compositions and methods of use |
| CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| NZ589036A (en) | 2008-05-16 | 2012-07-27 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| AU2013215254B2 (en) * | 2012-01-31 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| BR112014025339A8 (pt) * | 2012-04-16 | 2018-01-16 | Regeneron Pharma | método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo. |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| CN106589127A (zh) * | 2015-10-16 | 2017-04-26 | 钜川生物医药 | 一种pcsk9抗体及其制备方法和应用 |
| EP3895529B1 (en) | 2016-02-29 | 2026-04-29 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| JP2020514396A (ja) * | 2017-03-22 | 2020-05-21 | ザ チルドレンズ メディカル センター コーポレーション | Ｌｒｐ１結合剤およびその使用 |
| BR112020015112A2 (pt) | 2018-01-26 | 2021-04-06 | Regeneron Pharmaceuticals, Inc. | Anticorpos anti-tmprss2 e fragmentos que ligam antígenos |
-
2019
- 2019-01-24 BR BR112020015112-2A patent/BR112020015112A2/pt unknown
- 2019-01-24 DK DK19701428.5T patent/DK3638698T3/da active
- 2019-01-24 CN CN201980021929.3A patent/CN111936517B/zh active Active
- 2019-01-24 JP JP2020540397A patent/JP7834965B2/ja active Active
- 2019-01-24 SG SG11202006898TA patent/SG11202006898TA/en unknown
- 2019-01-24 KR KR1020207024526A patent/KR102911478B1/ko active Active
- 2019-01-24 PL PL19701428T patent/PL3638698T3/pl unknown
- 2019-01-24 SI SI201930061T patent/SI3638698T1/sl unknown
- 2019-01-24 MX MX2020007888A patent/MX2020007888A/es unknown
- 2019-01-24 MD MDE20200454T patent/MD3638698T2/ro unknown
- 2019-01-24 RS RS20210571A patent/RS61825B1/sr unknown
- 2019-01-24 EP EP19701428.5A patent/EP3638698B1/en active Active
- 2019-01-24 MA MA46731A patent/MA46731B1/fr unknown
- 2019-01-24 LT LTEP19701428.5T patent/LT3638698T/lt unknown
- 2019-01-24 US US16/256,560 patent/US10941213B2/en active Active
- 2019-01-24 KR KR1020257028979A patent/KR20250133488A/ko active Pending
- 2019-01-24 CA CA3089377A patent/CA3089377A1/en active Pending
- 2019-01-24 WO PCT/US2019/014978 patent/WO2019147831A1/en not_active Ceased
- 2019-01-24 CN CN202510504762.3A patent/CN120290578A/zh active Pending
- 2019-01-24 SM SM20210307T patent/SMT202100307T1/it unknown
- 2019-01-24 IL IL276164A patent/IL276164B2/en unknown
- 2019-01-24 HR HRP20210876TT patent/HRP20210876T1/hr unknown
- 2019-01-24 PT PT197014285T patent/PT3638698T/pt unknown
- 2019-01-24 IL IL312961A patent/IL312961A/en unknown
- 2019-01-24 ES ES19701428T patent/ES2864529T3/es active Active
- 2019-01-24 AU AU2019211406A patent/AU2019211406C1/en active Active
- 2019-01-24 HU HUE19701428A patent/HUE054403T2/hu unknown
-
2020
- 2020-07-21 ZA ZA2020/04494A patent/ZA202004494B/en unknown
- 2020-07-24 MX MX2024006462A patent/MX2024006462A/es unknown
-
2021
- 2021-01-20 US US17/153,684 patent/US11603413B2/en active Active
- 2021-05-27 CY CY20211100461T patent/CY1124182T1/el unknown
-
2023
- 2023-01-26 US US18/159,827 patent/US12065506B2/en active Active
- 2023-10-13 JP JP2023177262A patent/JP2024009962A/ja active Pending
-
2025
- 2025-06-04 AU AU2025204183A patent/AU2025204183A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11649295B2 (en) | Asymmetric multispecific antibodies | |
| JP2019122405A5 (enExample) | ||
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| JP2022519068A5 (enExample) | ||
| JP2020535799A5 (enExample) | ||
| JP2018183173A5 (enExample) | ||
| HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
| JP2012505654A (ja) | 抗体をヒト化及び親和性成熟する方法 | |
| GB2461546A (en) | Antigen binding polypeptides | |
| JP2020535799A (ja) | 新規の安定した抗体の可変領域フレームワークの組み合わせ | |
| US11319371B2 (en) | Anti-CD3 antibodies | |
| JP2021520832A5 (enExample) | ||
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| WO2013064701A2 (en) | Bispecific antibodies and methods for isolating same | |
| RU2008129111A (ru) | Антитела к ox40l и способы их применения | |
| JP2024095774A5 (enExample) | ||
| JP2021094022A5 (enExample) | ||
| RU2012122203A (ru) | Композиции и способы для лечения восполительных нарушений | |
| RU2008140947A (ru) | Антитела к egfl7 и способы их применения | |
| IL279901B1 (en) | Antibodies comprising a polypeptide inserted in framework 3 region | |
| JP2022515258A5 (enExample) | ||
| JP2023511898A5 (enExample) | ||
| JP2023551981A5 (enExample) | ||
| EP2041182A1 (en) | Framework selection | |
| RU2010122044A (ru) | УЛУЧШЕННЫЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Nogo-А И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ |